Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data — then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating. NEW YORK, July 9, 2026 /PRNewswire/ — Ionis Pharmaceuticals (NASDAQ: IONS) shares were…
Source: prnewswire
Country: United States